Antifungal drug resistance in Aspergillus

Journal of Infection

Volumn 41, Issue 3, 2000, Pages 203-220

  Moore, C B ^a   Sayers, N ^b   Mosquera, J ^b   Slaven, J ^b   Denning, D W ^b,c  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIOXIDANT; DICLOBUTRAZOLE; ENILCONAZOLE; ERGOSTEROL; FENARIMOL; FLUCONAZOLE; FLUSILAZOLE; ITRACONAZOLE; LIPOSOME; MICONAZOLE; NYSTATIN; OXIDIZING AGENT; POLYENE; POSACONAZOLE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; RAVUCONAZOLE; STEROL 14ALPHA DEMETHYLASE; TERBINAFINE; TIOCONAZOLE; TRIADIMEFON; TRIADIMENOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CROSS RESISTANCE; CULTURE MEDIUM; DILUTION; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TRANSPORT; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOULD; MUTATION; NONHUMAN;

EID: 0034523051     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2000.0747     Document Type: Review

References (125)

1. Itraconazole resistance in Aspergillus fumigatus
2. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
3. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus
4. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp
5. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B
6. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
7. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome of in a murine model of Aspergillus infection
8. Resistance to amphotericin B: Emerging clinical and microbiological patterns
9. Antifungal drug resistance in pathogenic fungi
10. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole
11. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents
12. Standardization of antifungal susceptibility and clinical relevance
13. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis
14. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole
15. In-vitro activity of terbinafine against Aspergillus species and comparison with itraconazole and amphotericin B [abstract WeP146]
16. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with amphotericin B
17. Distribution and activity of amphotericin B in humans
18. In-vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of Aspergillus fumigatus
19. Mechanisms and impact of antifungal drug resistance
20. Role of the number and position of double bonds in the four ring sterol nucleus in reaction with polyene antibiotics
21. Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols
22. How do the polyene macrolide antibiotics affect the cellular membrane properties?
23. Effect of amphotericin B on the metabolism of Aspergillus fumigatus
24. Characterization of the binding of amphotericin B to Saccharomyces cerevisiae and relationship to the antifungal effects
25. Nonsterol related resistance in Ustilago maydis to the polyene antifungals, amphotericin B and nystatin
26. Lipid composition and polyene antibiotic resistance of Candida albicans mutants
27. Action de l'amphotericine B sur la composition en sterols de Kluyveromyces bulgaricus et Kluyveromyces lactis
28. Polyene resistance in ergosterol producing strains of Candida albicans
29. Two types of resistance to polyene antibiotics in Candida albicans
30. Amphotericin B-induced oxidative damage and killing of Candida albicans
31. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B
32. Amphotericin B: Current understanding of mechanisms of action
33. Mechanism of inactivation of the polyene antibiotic amphotericin B
34. Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B
35. Role of oxidants in microbial pathophysiology
36. Amphotericin B protects cis-parinaric acid against peroxyl radical-induced oxidation: Amphotericin B as an antioxidant
37. A family of phospholipid autacoids: Occurrence, metabolism and bioactions
38. The polyene macrolide antibiotics
39. Reactive oxygen species associated with cell differentiation in Neurospora crassa
40. Fluorescence analysis of reactive oxygen species generated by six isolates of Aspergillus fumigatus
41. The Cu, Zn superoxide dismutases of Aspergillus flavus, Aspergillus niger, Aspergillus nidulans, Aspergillus terreus: Purification and biochemical comparison with the Aspergillus fumigatus Cu, Zn superoxide dismutase
42. Aspergillus fumigatus catalases: Cloning of an Aspergillus nidulans catalase B homologue and evidence for at least three catalases
43. Gliotoxin inactivates alcohol dehydrogenase by either covalent modification or free radical damage mediated by redox cycling
44. Increased amounts of the Aspergillus metabolite D-mannitol in tissue and serum of rats with experimental aspergillosis
45. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice
46. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis
47. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
48. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi
49. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi
50. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole
51. Susceptibility of Aspergillus strains from culture collections to amphotericin B and itraconazole
52. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
53. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus
54. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B
55. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin. B. Acquired resistance to itraconazole
56. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B
57. Antifungal susceptibility testing of Aspergilli isolated from confirmed aspergillosis infections
58. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates
59. Antifungal susceptibility of Aspergillus species isolated from invasive oral infection in neutropenic patients with hematologic malignancies
60. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi
61. A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus
62. Optimal susceptibility testing conditions to detect azole resistance of Aspergillus spp
63. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method
64. Invalidation of in-vitro susceptibility testing of Aspergillus flavus with itraconazole and amphotericin B using a murine model
65. Standardization of a hyphal inoculum of Aspergilli for amphotericin B susceptibility testing
66. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents
67. Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi
68. Multicenter evaluation of proposed standardised procedure for antifungal susceptibility testing of filamentous fungi
69. Comparison of three methods of determining MICs for filamentous fungi using different end point criteria and incubation periods
70. Colorimetric susceptibility testing for Aspergillus fumigatus: Comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar Blue tests
71. Molecular mechanisms of azole resistance in fungi
72. Clinical, cellular and molecular factors that contribute to antifungal drug resistance
73. Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8,24(28)-dien-3β,6α-diol
74. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta (5, 6) desaturation
75. Increased sensitivity of Candida albicans cells accumulating 14α-methylated sterols to active oxygen: Possible relevance to in vivo efficacies of azole antifungal agents
76. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
77. The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity
78. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents
79. A mutation in the 14α-demethylase gene of Uncinular necator that correlates with resistance to a sterol biosynthesis inhibitor
80. Altered P450 specificity associated with direct selection for fungal azole resistance
81. Molecular genetics of resistance in fungi to azole fungicides
82. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients
83. Isolation and characterisation of fluconazole and amphotericin B-resistant Candida albicans from blood of two patients with leukemia
84. Deletion of the Candida glabrata ERG3 and ERG11 genes - Effect on cell viability, cell growth, sterol composition, and antifungal susceptibility
85. Laboratory-induced fungicide resistance to benzimidazole and azole fungicides in Cercospora beticola
86. Molecular biological characterisation of an azole-resistant Candida glabrata isolate
87. ABC transporters: From microorganisms to man
88. Mechanism of resistance to fenarimol in Aspergillus nidulans
89. An energy dependent efflux mechanism for fenarimol in a wild-type strain and fenarimol-resistant mutants of Aspergillus nidulans
90. Differential accumulation of fenarimol by a wild-type isolate and fenarimol resistant isolates of Penicillium italicum
91. Accumulation of SBI fungicides in wild-type and fenarimol-resistant isolates of Penicillium italicum
92. A novel ATP-binding cassette transporter involved in multidrug resistance in the phytopathogenic fungus Penicillium digitatum
93. Multidrug resistance in Aspergillus nidulans involves novel ATP-binding cassette transporters
94. The gene that determines resistance to tioconazole and to acridine derivatives in Aspergillus nidulans may have a corresponding gene in Trichophyton rubrum
95. Resistance to fenarimol in Nectria haematococca var. cucurbitae
96. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
97. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene
98. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates
99. Molecular cloning and characterisation of a novel gene of Candida albicans CDR1, conferring multiple resistance to drugs and antifungals
100. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance
101. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
102. Genes encoding multiple drug resistance-like proteins in Aspergillus fumigatus and Aspergillus flavus
103. Expression of atrC-encoding a novel member of the ATP binding cassette transporter family in Aspergillus nidulans-is sensitive to cycloheximide
104. Fungal transporters involved in efflux of natural toxic compounds and fungicides
105. Induced expression of a novel Aspergillus fumigatus putative drug efflux gene in response to itraconazole
106. Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent
107. Fungicide resistance in crop pathogens: How can it be managed?
108. Characterization of fenarimol-resistant mutants of Aspergillus nidulans
109. Genetic study of a triadimefon-resistant mutant of Aspergillus nidulans
110. Laboratory resistance to fungicides which inhibit ergosterol biosynthesis in Penicillium italicum
111. Stepwise development of laboratory resistance to DMI-fungicides in Penicillium italicum
112. In vitro emergence of resistant fungal strains after serial subculturing on gradiently increasing concentrations of five different antifungal agents
113. Fungicide resistance: The assessment of risk?
114. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for anti-fungal drug development
115. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity and selectivity in vitro [abstract F72]
116. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
117. UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections. Clinical efficacy in chronic invasive aspergillosis
118. The efficacy and tolerability of UK 109,496 (voriconazole) in the treatment of invasive aspergillosis (IA)
119. SCH56592 is a potent inhibitor of sterol C14 demethylation in fungi
120. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis and cryptococcosis
121. Comparison of azoles against Aspergilli in vitro and in an experimental model of pulmonary aspergillosis